<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="publisher-id">JCTH</journal-id><journal-title-group><journal-title>Journal of Clinical and Translational Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2225-0719</issn><issn pub-type="epub">2310-8819</issn><publisher><publisher-name>XIA &#x00026; HE Publishing Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7132016</article-id><article-id pub-id-type="publisher-id">JCTH.2020.00018</article-id><article-id pub-id-type="doi">10.14218/JCTH.2020.00018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies</article-title><alt-title alt-title-type="running-head-verso">Feng G. <italic>et al</italic>: COVID-19 and liver dysfunction</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Gong</given-names></name><xref ref-type="author-notes" rid="afn1">#</xref><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Kenneth I.</given-names></name><xref ref-type="author-notes" rid="afn1">#</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Qin-Qin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rios</surname><given-names>Rafael S.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Targher</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Byrne</surname><given-names>Christopher D.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Poucke</surname><given-names>Sven Van</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Wen-Yue</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Ming-Hua</given-names></name><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><aff id="aff1">
<label>1</label>Xi&#x02019;an Medical University, Xi&#x02019;an, China</aff><aff id="aff2">
<label>2</label>NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China</aff><aff id="aff3">
<label>3</label>Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy</aff><aff id="aff4">
<label>4</label>Southampton National Institute for Health Research Biomedical Research Center, University Hospital Southampton, Southampton General Hospital, Southampton, UK</aff><aff id="aff5">
<label>5</label>Ziekenhuis Oost-Limburg, Department of Anesthesiology, Critical Care, Emergency Medicine and Pain Therapy, Genk, Belgium</aff><aff id="aff6">
<label>6</label>Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China</aff><aff id="aff7">
<label>7</label>Institute of Hepatology, Wenzhou Medical University, Wenzhou, China</aff><aff id="aff8">
<label>8</label>Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China</aff></contrib-group><author-notes><corresp id="cor1"><sup>*</sup><bold>Correspondence to:</bold> Ming-Hua Zheng, NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou 325000, China. Tel: +86-577-55579622, Fax: +86-577-55578522, E-mail: <email xlink:href="mailto:zhengmh@wmu.edu.cn">zhengmh@wmu.edu.cn</email></corresp><fn id="afn1"><p><sup>#</sup>These authors contributed equally to this study.</p></fn><fn fn-type="other"><p>Funding: This work was supported by grants from the National Natural Science Foundation of China (81500665), High Level Creative Talents from Department of Public Health in Zhejiang Province and Project of New Century 551 Talent Nurturing in Wenzhou. GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy. CDB is supported in part by grants from the Southampton National Institute for Health Research Biomedical Research Centre (IS-BRC-20004), UK.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflict of interests related to this article.</p></fn><fn fn-type="con"><p>Design and data interpretation (MHZ, GF, KIZ, QQY, WYL), manuscript writing (GF, KIZ, RSR), critical revision of the manuscript (MHZ, GT, CDB, SVP). All authors reviewed and commented on the manuscript and approved the final version.</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="ppub"><day>28</day><month>3</month><year>2020</year></pub-date><volume>8</volume><issue>1</issue><fpage>18</fpage><lpage>24</lpage><history><date date-type="received"><day>8</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>16</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Authors.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" license-type="open-access"><license-p>This article has been published under the terms of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. &#x0201c;This article has been published in <italic>Journal of Clinical and Translational Hepatology</italic> at DOI: <ext-link ext-link-type="doi" xlink:href="10.14218/JCTH.2020.00018">10.14218/JCTH.2020.00018</ext-link> and can also be viewed on the Journal&#x02019;s website at <uri xlink:type="simple" xlink:href="http://www.jcthnet.com">http://www.jcthnet.com</uri>&#x0201d;.</license-p></license></permissions><abstract><title>Abstract</title><p>The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19-related liver damage/dysfunction is due mainly to the viral infection per se or other coexisting conditions, such as the use of potentially hepatotoxic drugs and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Based on the current evidence from case reports and case series, this review article focuses on the demographic and clinical characteristics, potential mechanisms, and treatment options for COVID-19-related liver dysfunction. This review also describes the geographical and demographic distribution of COVID-19-related liver dysfunction, as well as possible underlying mechanisms linking COVID-19 to liver dysfunction, in order to facilitate future drug development, prevention, and control measures for COVID-19.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>Liver dysfunction</kwd><kwd>SARS-CoV-2</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a serious threat to global public health.<xref rid="b1" ref-type="bibr">1</xref><sup>,</sup><xref rid="b2" ref-type="bibr">2</xref> Although the virus appears to be only partially similar to severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, all of these viral infections are responsible for severe and potentially lethal acute respiratory syndromes in humans.<xref rid="b3" ref-type="bibr">3</xref> Unfortunately, to date, there are no specific/targeted drugs, or vaccines, and the number of SARS-CoV-2-positive patients is growing in many parts of the world. The world and China map showing the geographical distribution of coronavirus disease 2019 (COVID-19) is shown in <xref ref-type="fig" rid="f01">Figure 1</xref>; the cut-off date for this data extraction was March 5, 2020.<xref rid="b4" ref-type="bibr">4</xref></p><fig id="f01" position="float"><label>Fig. 1.</label><caption><title>Geographical distribution of COVID-19, using the cut-off date for data extraction of March 5, 2020.</title></caption><graphic xlink:href="JCTH-8-018-g001"/></fig><p>Surprisingly, in addition to the acute respiratory symptoms, patients with COVID-19 also have varying degrees of liver damage/dysfunction. For example, Chen <italic>et al.</italic><xref rid="b5" ref-type="bibr">5</xref> showed that more than a third of COVID-19 patients have some liver function test abnormalities. Most of these infected patients had mild-to-moderate elevations of serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels; one patient had severely elevated serum aminotransferases (ALT of 7590 U/L, AST of 1445 U/L).<xref rid="b5" ref-type="bibr">5</xref> Since COVID-19-related liver dysfunction is now attracting widespread attention, this review discusses the epidemiological characteristics, the potential mechanisms, and the treatment options for liver dysfunction induced by COVID-19.</p></sec><sec id="s2"><title>Epidemiological characteristics of COVID-19-related liver dysfunction</title><p>To better understand the distribution of COVID-19-related liver dysfunction in different regions of the world, we searched the available literature between December 11, 2019 and February 20, 2020. The literature search focused on initial case reports and case series covering COVID-19 patients, with a clear description of liver function tests and results. All case reports without any data on patients&#x02019; liver function tests were excluded. Finally, we included 14 eligible studies, including 5 case reports (<xref rid="t01" ref-type="table">Table 1</xref>) and 9 case series (<xref rid="t02" ref-type="table">Table 2</xref>).<xref rid="b5" ref-type="bibr">5</xref><sup>&#x02013;</sup><xref rid="b18" ref-type="bibr">18</xref> By reviewing these 14 studies, we have described geographical and demographic characteristics of COVID-19-related liver dysfunction (as summarized below).</p><table-wrap id="t01" position="float"><label>Table 1.</label><caption><title>Demographic and liver function characteristics of patients with COVID-19 based on the first case reports in three countries</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><td align="left" rowspan="2" colspan="1"> Author, Year</td><td align="left" rowspan="2" colspan="1"> Country</td><td align="left" rowspan="2" colspan="1"> Age (years)</td><td align="left" rowspan="2" colspan="1"> Sex</td><td align="left" rowspan="2" colspan="1"> AST (IU/L)</td><td align="left" rowspan="2" colspan="1"> ALT (IU/L)</td><td align="left" rowspan="2" colspan="1"> COVID-19 Disease severity</td><td align="left" rowspan="2" colspan="1">Prior history of liver diseases</td><td align="center" colspan="3" rowspan="1">Drugs</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotic drugs</td><td align="left" rowspan="1" colspan="1">Antiviral drugs</td><td align="left" rowspan="1" colspan="1">Antifungal drugs</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Zhang YH, 2020<xref rid="b6" ref-type="bibr">6</xref></td><td align="left" rowspan="1" colspan="1">China (Haikou)</td><td align="left" rowspan="1" colspan="1">3 months</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Non-severe</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Azithromycin, Ceftazidime</td><td align="left" rowspan="1" colspan="1">Paramivir</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Chen F, 2020<xref rid="b7" ref-type="bibr">7</xref></td><td align="left" rowspan="1" colspan="1">China (Wuhan)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">Meropenem, Linezolid, Oseltamivir</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Cai JH, 2020<xref rid="b8" ref-type="bibr">8</xref></td><td align="left" rowspan="1" colspan="1">China (Shanghai)</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">Non-severe</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Levofloxacin</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Holshue ML, 2020<xref rid="b9" ref-type="bibr">9</xref></td><td align="left" rowspan="1" colspan="1">United States</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">72 (16.4)<xref ref-type="fn" rid="table1fn2"><sup>*</sup></xref></td><td align="left" rowspan="1" colspan="1">124 (30.3)<xref ref-type="fn" rid="table1fn2"><sup>*</sup></xref></td><td align="left" rowspan="1" colspan="1">Non-severe</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Silverstein WK, 2020<xref rid="b10" ref-type="bibr">10</xref></td><td align="left" rowspan="1" colspan="1">Canada</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">Non-severe</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p>AST: aspartate aminotransferase. ALT: alanine aminotransferase. Liver diseases: any liver disease that can cause serum liver enzyme changes, such as viral hepatitis, autoimmune hepatitis, etc. NA: not available. Normal ranges for AST and ALT: AST &#x0003c; 40 IU/L and ALT &#x0003c; 40 IU/L.</p></fn><fn id="table1fn2"><label>*</label><p>Standard deviation of liver enzyme fluctuations during hospitalization</p></fn></table-wrap-foot></table-wrap><table-wrap id="t02" position="float"><label>Table 2.</label><caption><title>Main characteristics related to liver disease in patients with COVID-19 infection in different Chinese regions based on a series of case reports</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><td align="left" rowspan="2" colspan="1">Author, Year</td><td align="left" rowspan="2" colspan="1">Country</td><td align="left" rowspan="2" colspan="1">Sample size (n)</td><td align="left" rowspan="2" colspan="1">Abnormal AST (%)</td><td align="left" rowspan="2" colspan="1">AST (IU/L)</td><td align="left" rowspan="2" colspan="1">Abnormal ALT (%)</td><td align="left" rowspan="2" colspan="1">ALT (IU/L)</td><td align="left" rowspan="2" colspan="1">Male, n (%)</td><td align="left" rowspan="2" colspan="1">Age (years)</td><td align="center" colspan="2" rowspan="1">Disease severity</td><td align="left" rowspan="2" colspan="1">History of liver diseases (%)</td><td align="center" colspan="3" rowspan="1">Drugs</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe (%)</td><td align="left" rowspan="1" colspan="1">Non-severe (%)</td><td align="left" rowspan="1" colspan="1">Antibiotic drugs (%)</td><td align="left" rowspan="1" colspan="1">Antiviral drugs (%)</td><td align="left" rowspan="1" colspan="1">Antifungal drugs (%)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Guan WJ 2020<xref rid="b11" ref-type="bibr">11</xref></td><td align="left" rowspan="1" colspan="1">China (Multi-center)</td><td align="left" rowspan="1" colspan="1">1099</td><td align="left" rowspan="1" colspan="1">168 (22.2)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">158 (21.3)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">640 (58.2)</td><td align="left" rowspan="1" colspan="1">47.0 (35.0&#x02013;58.0)</td><td align="left" rowspan="1" colspan="1">173 (15.7)</td><td align="left" rowspan="1" colspan="1">926 (84.3)</td><td align="left" rowspan="1" colspan="1">23 (2.1)</td><td align="left" rowspan="1" colspan="1">632 (57.5)</td><td align="left" rowspan="1" colspan="1">393 (35.8)</td><td align="left" rowspan="1" colspan="1">30 (2.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Xu XW, 2020<xref rid="b12" ref-type="bibr">12</xref></td><td align="left" rowspan="1" colspan="1">China (Zhejiang)</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">10 (16.1)</td><td align="left" rowspan="1" colspan="1">26 (20&#x02013;32)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">22 (14&#x02013;34)</td><td align="left" rowspan="1" colspan="1">36 (58.1)</td><td align="left" rowspan="1" colspan="1">41.0 (32.0&#x02013;52.0)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">7 (11.3)</td><td align="left" rowspan="1" colspan="1">28 (45.2)</td><td align="left" rowspan="1" colspan="1">55 (88.7)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Chen NS, 2020<xref rid="b5" ref-type="bibr">5</xref></td><td align="left" rowspan="1" colspan="1">China (Wuhan)</td><td align="left" rowspan="1" colspan="1">99</td><td align="left" rowspan="1" colspan="1">35 (35.3)</td><td align="left" rowspan="1" colspan="1">34 (26&#x02013;48)</td><td align="left" rowspan="1" colspan="1">28 (28.2)</td><td align="left" rowspan="1" colspan="1">39 (22&#x02013;53)</td><td align="left" rowspan="1" colspan="1">67 (68.7)</td><td align="left" rowspan="1" colspan="1">55.5 &#x000b1; 35.1</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">11 (11.1)</td><td align="left" rowspan="1" colspan="1">70 (70.7)</td><td align="left" rowspan="1" colspan="1">75 (75.8)</td><td align="left" rowspan="1" colspan="1">15 (15.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Chen L, 2020<xref rid="b13" ref-type="bibr">13</xref></td><td align="left" rowspan="1" colspan="1">China (Wuhan)</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">7 (24.1)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">5 (17.2)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">21 (72.4)</td><td align="left" rowspan="1" colspan="1">56.0<xref ref-type="fn" rid="table2fn2"><sup>*</sup></xref></td><td align="left" rowspan="1" colspan="1">14 (48.3)</td><td align="left" rowspan="1" colspan="1">15 (51.7)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Wang DW, 2020<xref rid="b14" ref-type="bibr">14</xref></td><td align="left" rowspan="1" colspan="1">China (Wuhan)</td><td align="left" rowspan="1" colspan="1">138</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">31 (24&#x02013;51)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">24 (16&#x02013;40)</td><td align="left" rowspan="1" colspan="1">75 (54.3)</td><td align="left" rowspan="1" colspan="1">56.0 (42.0&#x02013;68.0)</td><td align="left" rowspan="1" colspan="1">36 (26.1)</td><td align="left" rowspan="1" colspan="1">102 (73.9)</td><td align="left" rowspan="1" colspan="1">4 (2.9)</td><td align="left" rowspan="1" colspan="1">89 (64.5)</td><td align="left" rowspan="1" colspan="1">124 (89.9)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Pan F, 2020<xref rid="b15" ref-type="bibr">15</xref></td><td align="left" rowspan="1" colspan="1">China (Wuhan)</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">32 &#x000b1; 20 (15&#x02013;95)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">42 &#x000b1; 31 (12&#x02013;107)</td><td align="left" rowspan="1" colspan="1">6 (28.6)</td><td align="left" rowspan="1" colspan="1">40.0 &#x000b1; 9.0</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">21 (100.0)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Liu C, 2020<xref rid="b16" ref-type="bibr">16</xref></td><td align="left" rowspan="1" colspan="1">China (Multi-center)</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">2 (6.2)</td><td align="left" rowspan="1" colspan="1">25 (19&#x02013;32)</td><td align="left" rowspan="1" colspan="1">9 (28.1)</td><td align="left" rowspan="1" colspan="1">26 (17&#x02013;46)</td><td align="left" rowspan="1" colspan="1">20 (62.5)</td><td align="left" rowspan="1" colspan="1">38.5 (26.3&#x02013;45.8)</td><td align="left" rowspan="1" colspan="1">4 (12.5)</td><td align="left" rowspan="1" colspan="1">28 (87.5)</td><td align="left" rowspan="1" colspan="1">1 (3.13)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Huang C 2020<xref rid="b17" ref-type="bibr">17</xref></italic></td><td align="left" rowspan="1" colspan="1">China (Wuhan)</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">15 (36.6)</td><td align="left" rowspan="1" colspan="1">34 (26&#x02013;48)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">32 (21&#x02013;50)</td><td align="left" rowspan="1" colspan="1">30 (73.2)</td><td align="left" rowspan="1" colspan="1">49.0 (41.0&#x02013;58.0)</td><td align="left" rowspan="1" colspan="1">13 (31.7)</td><td align="left" rowspan="1" colspan="1">28 (68.3)</td><td align="left" rowspan="1" colspan="1">1 (2.4)</td><td align="left" rowspan="1" colspan="1">41 (100.0%)</td><td align="left" rowspan="1" colspan="1">38 (92.7%)</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Chen HJ 2020<xref rid="b18" ref-type="bibr">18</xref></td><td align="left" rowspan="1" colspan="1">China (Wuhan)</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">3 (33.3)</td><td align="left" rowspan="1" colspan="1">24 (21&#x02013;119)</td><td align="left" rowspan="1" colspan="1">3 (33.3)</td><td align="left" rowspan="1" colspan="1">16 (11&#x02013;58)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">28 (26&#x02013;34)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">9 (100.0)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">9 (100.0%)</td><td align="left" rowspan="1" colspan="1">6 (66.7%)</td><td align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><p>Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; NA, not available. Liver diseases: any liver disease that can cause liver enzyme changes, such as viral hepatitis, autoimmune hepatitis, etc. 
Normal range for AST and ALT: AST &#x0003c; 40 IU/L and ALT &#x0003c; 40 IU/L.</p></fn><fn id="table2fn2"><label>*</label><p> Median, no interquartile range</p></fn></table-wrap-foot></table-wrap><sec id="s2-1"><title>Geographical distribution of COVID-19-related liver dysfunction</title><p>In two Chinese multicenter surveys, one of which was led by the First Affiliated Hospital of Guangzhou Medical University, including 552 hospitals in 31 provinces/provincial municipalities through January 29th, 2020 and the other was led by the First Hospital of Lanzhou University including 7 hospitals, a considerable number of patients with COVID-19 had some abnormalities in liver function tests.<xref rid="b11" ref-type="bibr">11</xref><sup>,</sup><xref rid="b16" ref-type="bibr">16</xref> In particular, 6.2% to 22.2% of patients had increased serum AST levels (<xref ref-type="fig" rid="f02">Fig. 2</xref>) and 21.3% to 28.1% of patients had increased serum ALT levels, respectively.<xref rid="b11" ref-type="bibr">11</xref><sup>,</sup><xref rid="b16" ref-type="bibr">16</xref> Of the six studies performed in Wuhan, China,<xref rid="b5" ref-type="bibr">5</xref><sup>,</sup><xref rid="b13" ref-type="bibr">13</xref><sup>&#x02013;</sup><xref rid="b15" ref-type="bibr">15</xref><sup>,</sup><xref rid="b17" ref-type="bibr">17</xref><sup>,</sup><xref rid="b18" ref-type="bibr">18</xref> only four included data on the proportion of patients with abnormal liver function test results. Specifically, in these four studies, the proportion of infected patients with increased serum AST levels ranged from 24.1% to 36.6% (<xref ref-type="fig" rid="f02">Fig. 2</xref>).<xref rid="b5" ref-type="bibr">5</xref><sup>,</sup><xref rid="b13" ref-type="bibr">13</xref><sup>,</sup><xref rid="b17" ref-type="bibr">17</xref><sup>,</sup><xref rid="b18" ref-type="bibr">18</xref> In a survey from Zhejiang Province, China, the proportion of patients with increased serum AST levels was only 16.1%, whereas the proportion of those with increased serum ALT levels was not specified.<xref rid="b12" ref-type="bibr">12</xref> It seems likely that the proportion of infected patients with increased serum AST levels in Wuhan (i.e. the area in which the epidemic of COVID-19 started) is much greater than cases reported outside Wuhan. It is plausible to speculate that there may have been a higher viral load of COVID-19 in exposed patients in Wuhan, where the infection began and was concentrated in a greater proportion of the population.</p><fig id="f02" position="float"><label>Fig. 2.</label><caption><title>Proportion of patients with liver dysfunction in Chinese regions: Wuhan and outside Wuhan.</title></caption><graphic xlink:href="JCTH-8-018-g002"/></fig></sec><sec id="s2-2"><title>Sex distribution of COVID-19-related liver dysfunction</title><p>A total of six case series reporting the percentage of abnormal liver function test results amongst COVID-19 patients suggested that the proportion of infected men with increased serum AST levels was higher than that observed in infected women.<xref rid="b5" ref-type="bibr">5</xref><sup>,</sup><xref rid="b11" ref-type="bibr">11</xref><sup>&#x02013;</sup><xref rid="b13" ref-type="bibr">13</xref><sup>,</sup><xref rid="b16" ref-type="bibr">16</xref><sup>,</sup><xref rid="b17" ref-type="bibr">17</xref> In fact, in these case series, the proportions of infected men with increased serum AST levels were, respectively, 68.7%, 58.2%, 58.1%, 72.4%, 62.8% and 73.2%, whereas the proportions of infected women were, respectively, 31.3%, 41.8%, 41.9%, 27.6%, 37.2% and 26.8%. It is possible to hypothesize that infected men are more predisposed to develop COVID-19-associated liver dysfunction than infected women, and we suggest that further research is required to better understand this sex-related difference.</p></sec><sec id="s2-3"><title>Age distribution of COVID-19-related liver dysfunction</title><p>Of the five case reports, three were in children and two were in adults. The age of children ranged from 3 months to 7 years, whereas the age of adult patients ranged from 35 to 56 years. None of these children had abnormal serum liver enzymes and, therefore, it is possible to hypothesize that older age is associated with a higher likelihood of liver damage/dysfunction. However, further studies are needed to confirm this finding. We look forward to more case reports/case series on COVID-19-related liver damage/dysfunction in different age groups in the future.</p></sec></sec><sec id="s3"><title>Putative mechanisms of COVID-19-related liver dysfunction</title><sec id="s3-1"><title>Angiotensin-converting enzyme <italic>(ACE)2-mediated liver dysfunction</italic></title><p>Whether SARS-CoV-2 has direct adverse effects on liver function is currently not known. Some studies have suggested that SARS-CoV-2 predominantly enters alveolar epithelial cells through the human ACE2 receptor.<xref rid="b19" ref-type="bibr">19</xref><sup>,</sup><xref rid="b20" ref-type="bibr">20</xref> Therefore, the lung is considered the main target organ of SARS-CoV-2 infection. However, previous studies have found that bile duct epithelial cells may also express ACE2 receptor at a concentration 20 times higher than in hepatocytes and these findings suggest that SARS-CoV-2 infection might also cause bile duct epithelial cell damage.<xref rid="b21" ref-type="bibr">21</xref><sup>,</sup><xref rid="b22" ref-type="bibr">22</xref> However, significant increases in circulating levels of serum alkaline phosphatase, bilirubin or gamma-glutamyltransferase (that may reflect bile duct injury) have been rarely reported in COVID-19 patients.<xref rid="b9" ref-type="bibr">9</xref> Liver histopathologic features from COVID-19 patients also did not show any significant damage in hepatocytes or bile duct cells.<xref rid="b23" ref-type="bibr">23</xref> For this reason, it is reasonable to assume that COVID-19-related liver dysfunction is more likely due to secondary liver damage than the use of hepatotoxic therapies or the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, or multiple organ dysfunction.</p></sec><sec id="s3-2"><title>Drugs</title><p>During the course of the COVID-19 epidemic, many infected patients have been treated with antipyretic agents. Most of these medications contain acetaminophen, which is a drug recognized as being able to cause significant liver damage or induce liver failure.<xref rid="b23" ref-type="bibr">23</xref> It is known that an acute ingestion of &#x0003e;7.5 to 10 g of acetaminophen in adults or 150 to 200 mg/kg in children is likely to cause hepatotoxicity.<xref rid="b24" ref-type="bibr">24</xref> Although the US Food and Drug Administration Advisory Committee has proposed a decrease in the maximum daily dosage of acetaminophen from 4 to 3 g, and the maximum individual dosage from 1 to 0.65 g, (relegating 500-mg tablets to prescription status), these recommendations have not been implemented worldwide.<xref rid="b25" ref-type="bibr">25</xref> In addition, although there is currently no targeted antiviral treatment for COVID-19, many infected patients have also been treated with some antiviral drugs, such as oseltamivir, abidol or lopinavir, which may have some hepatotoxic effects.</p></sec><sec id="s3-3"><title>Systemic inflammatory response syndrome</title><p>Although many COVID-19 patients were not too unwell, this infection in some patients has resulted in sudden deterioration, ending in multiple organ failure. Most experts believe that the occurrence of multiple organ failure is mainly related to the sudden initiation of an inflammatory &#x0201c;storm&#x0201d; in the critically ill COVID-19 patients.<xref rid="b26" ref-type="bibr">26</xref> The so-called inflammatory &#x0201c;storm&#x0201d;, or systemic inflammatory response syndrome, is strongly related to activation of both natural and cellular immunity that is triggered by COVID-19 infection.<xref rid="b27" ref-type="bibr">27</xref> In fact, the virus is able to directly induce multiple proinflammatory signals via toll-like receptors (TLRs) and activation of killer T lymphocytes.<xref rid="b28" ref-type="bibr">28</xref> The activated T lymphocytes then attack the infected body cells, leading to their apoptosis and necrosis, until T lymphocytes are depleted. Damage-related pattern molecules released by dead infected cells can further amplify some inflammatory signals, such as TLRs. At the same time, T-lymphocyte depletion cannot control viral and bacterial infections, thereby activating multiple inflammatory signaling pathways, which lead to macrophage activation and secondary inflammatory reactions. Subsequently, when more inflammatory cytokines are released, more cell damage and necrosis are observed (<xref ref-type="fig" rid="f03">Fig. 3</xref>). Such a vicious cycle is capable of causing multiple injuries, not only to the lungs but also to the liver, heart, and kidneys.</p><fig id="f03" position="float"><label>Fig. 3.</label><caption><title><bold>Schematic diagram showing the systemic inflammatory response syndrome induced by SARS-CoV2.</bold> After the SARS-CoV-2 infection, pathogenic T cells are rapidly activated, producing granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-6 and other proinflammatory factors. GM-CSF will further activate CD14<sup>+</sup>CD16<sup>+</sup> inflammatory monocytes, producing a larger amount of IL-6 and other proinflammatory factors, and thereby inducing an inflammatory &#x0201c;storm&#x0201d; that leads to immune damage to other organs, such as the lungs and the liver. Both IL-6 and GM-CSF are two key proinflammatory factors that trigger the inflammatory &#x0201c;storm&#x0201d; in patients with COVID-19.</title></caption><graphic xlink:href="JCTH-8-018-g003"/></fig></sec><sec id="s3-4"><title>Hypoxia-reperfusion dysfunction</title><p>Hypoxia and shock induced by COVID-19-related complications (such as respiratory distress syndrome, systemic inflammatory response syndrome, and multiple organ failure) may also cause hepatic ischemia and hypoxia-reperfusion dysfunction. Experimental data showed that hepatic cell death and inflammatory cell infiltration caused by hypoxia can be seen both <italic>in vivo</italic> and <italic>in vitro</italic> models of hepatic ischemia and hypoxia.<xref rid="b29" ref-type="bibr">29</xref> This suggests that oxygen reduction and lipid accumulation in hepatocytes during shock and hypoxic conditions may lead to cell death. The subsequent marked increase in reactive oxygen species and their peroxidation products can act as a second messenger, activating redox-sensitive transcription factors, and further amplifying the release of multiple proinflammatory factors, causing liver damage.<xref rid="b30" ref-type="bibr">30</xref> All the aforementioned findings suggest that pneumonia-associated hypoxia is one of the most important factors causing secondary liver injury in COVID-19 patients.</p><p>In summary, the COVID-19-related liver dysfunction may be considered as the result of secondary liver damage caused mainly by several factors, such as the use of potentially hepatotoxic drugs, systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ failure. In addition, critically ill COVID-19 patients with severe liver dysfunction are also more likely to have a poorer prognosis.</p></sec></sec><sec id="s4"><title>Treatment options for COVID-19-related liver dysfunction</title><p>Presently, there is no specific treatment for COVID-19 infection.<xref rid="b31" ref-type="bibr">31</xref> Therefore, the cornerstone of COVID-19 management is patient isolation and supportive medical care where necessary, including pulmonary ventilation and prevention of the underlying inflammatory &#x0201c;storm&#x0201d; as well.<xref rid="b32" ref-type="bibr">32</xref></p><p>From the findings discussed above, however, we believe that it is also reasonable to explore novel treatments for COVID-19 targeting of the ACE2 receptor. The ACE2 cellular receptor is highly expressed in human lung tissues, gastrointestinal tract, liver, vascular endothelial cells, and arterial smooth muscle cells.<xref rid="b33" ref-type="bibr">33</xref> In addition, skin, nasal cavity, and oral mucosa basal cells also express the ACE2 receptor.<xref rid="b27" ref-type="bibr">27</xref> All organs with high expression of the ACE2 receptor may be targeted by SARS-CoV-2 infection.<xref rid="b34" ref-type="bibr">34</xref> Activation of the ACE2/Ang (1-7)/Mas signaling pathway or inhibition of the ACE/Ang II/AT1R pathway could be potential pathways for the treatment of COVID-19. For SARS-CoV-2-infected patients, both ACE-inhibitors and angiotensin-II-receptor antagonists might be used not only for treating high blood pressure but also for reducing systemic inflammatory response and improving patient mortality.<xref rid="b35" ref-type="bibr">35</xref></p><p>Recently, Chen <italic>et al.</italic><xref rid="b36" ref-type="bibr">36</xref> reported that glycyrrhizic acid derivatives might also have antiviral activity against SARS-CoV-2. Glycyrrhizic acid is one of the first-line drugs for anti-inflammatory protection in liver disease, and it has been used in clinical practice for many years.<xref rid="b37" ref-type="bibr">37</xref> In particular, glycyrrhizic acid is a triterpene glycoside isolated from the root of the licorice plant. ACE2 is a cellular type I membrane protein that is mostly expressed in the lungs, heart, kidneys, and intestine. Full-length ACE2 consists of an N-terminal peptidase domain and a C-terminal collectrin-like domain that ends with a single trans-membrane helix and a &#x0223c;40-residue intracellular segment.<xref rid="b38" ref-type="bibr">38</xref> Glycyrrhizin has the potential to bind to ACE2 receptor with an estimated &#x00394;G (kcal/mol) of -9, with the binding sites of ARG-559, GLN-388, ARG-393, and ASP-30.<xref rid="b36" ref-type="bibr">36</xref></p></sec><sec id="s5"><title>Conclusions</title><p>Our review shows the following: (1) In highly epidemic areas of COVID-19 infection, such as Wuhan, China, the proportion of infected patients with abnormal liver function test results (mainly elevated serum AST levels) is greater than that observed in regions where a smaller proportion of cases of COVID-19 infection in the population have occurred. (2) The proportion of infected patients with elevated serum transaminase levels is higher in adults than in children and in men than in women, respectively. However, we suggest that further studies are needed to confirm these preliminary observations. In the meantime, we believe that the front-line medical staff should pay attention to liver function tests in patients infected with COVID-19. For those patients with a pre-existing history of liver diseases (especially older patients), special attention should be paid to monitoring hepatic changes caused by COVID-19, whilst carefully identifying the cause of the liver dysfunction.<xref rid="b39" ref-type="bibr">39</xref> We also recommend that front-line medical staff should assess the use of appropriate hepatoprotective therapies, especially in patients with pre-existing liver disease, in order to attenuate the potentially deleterious impact of COVID-19-related liver damage/dysfunction.</p></sec></body><back><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>FS</given-names></name></person-group><article-title>Liver injury in COVID-19: management and challenges</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2468-1253(20)30057-1</pub-id></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Coronavirus disease 2019 (COVID-19) situation report-49</article-title><year>2020</year><comment>Available from: <uri xlink:type="simple" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200309-sitrep-49-covid-19.pdf?sfvrsn=70dabe61_4">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200309-sitrep-49-covid-19.pdf?sfvrsn=70dabe61_4</uri></comment></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>DJ</given-names></name><name><surname>Xiao</surname><given-names>MF</given-names></name><name><surname>Wang</surname><given-names>JC</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>ZX</given-names></name><etal/></person-group><article-title>[2019-novel coronavirus infection in a three-month-old baby]</article-title><source>Zhonghua Er Ke Za Zhi</source><year>2020</year><volume>58</volume><fpage>E006</fpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.0578-1310.2020.0006</pub-id><pub-id pub-id-type="pmid">32043842</pub-id></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>ZS</given-names></name><name><surname>Zhang</surname><given-names>FR</given-names></name><name><surname>Xiong</surname><given-names>RH</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>XF</given-names></name><etal/></person-group><article-title>[First case of severe childhood novel coronavirus pneumonia in China]</article-title><source>Zhonghua Er Ke Za Zhi</source><year>2020</year><volume>58</volume><fpage>E005</fpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.0578-1310.2020.0005</pub-id><pub-id pub-id-type="pmid">32045966</pub-id></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>XS</given-names></name><name><surname>Ge</surname><given-names>YL</given-names></name><name><surname>Xia</surname><given-names>AM</given-names></name><name><surname>Chang</surname><given-names>HL</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><etal/></person-group><article-title>[First case of 2019 novel coronavirus infection in children in Shanghai]</article-title><source>Zhonghua Er Ke Za Zhi</source><year>2020</year><volume>58</volume><fpage>86</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.0578-1310.2020.02.002</pub-id><pub-id pub-id-type="pmid">32102141</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><name><surname>DeBolt</surname><given-names>C</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><name><surname>Lofy</surname><given-names>KH</given-names></name><name><surname>Wiesman</surname><given-names>J</given-names></name><name><surname>Bruce</surname><given-names>H</given-names></name><etal/></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>929</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>WK</given-names></name><name><surname>Stroud</surname><given-names>L</given-names></name><name><surname>Cleghorn</surname><given-names>GE</given-names></name><name><surname>Leis</surname><given-names>JA</given-names></name></person-group><article-title>First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>734</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30370-6</pub-id><pub-id pub-id-type="pmid">32061312</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>CQ</given-names></name><name><surname>He</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>XW</given-names></name><name><surname>Wu</surname><given-names>XX</given-names></name><name><surname>Jiang</surname><given-names>XG</given-names></name><name><surname>Xu</surname><given-names>KJ</given-names></name><name><surname>Ying</surname><given-names>LJ</given-names></name><name><surname>Ma</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series</article-title><source>BMJ</source><year>2020</year><volume>368</volume><fpage>m606</fpage><pub-id pub-id-type="doi">10.1136/bmj.m606</pub-id><pub-id pub-id-type="pmid">32075786</pub-id></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>HG</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><etal/></person-group><article-title>[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi</source><year>2020</year><volume>43</volume><fpage>E005</fpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1001-0939.2020.0005</pub-id><pub-id pub-id-type="pmid">32026671</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x02013;infected pneumonia in Wuhan, China</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Gui</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia</article-title><source>Radiology</source><year>2020</year><fpage>200370</fpage><pub-id pub-id-type="doi">10.1148/radiol.2020200370</pub-id><pub-id pub-id-type="pmid">32053470</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>ZC</given-names></name><name><surname>Shao</surname><given-names>CX</given-names></name><name><surname>Zhang</surname><given-names>HG</given-names></name><name><surname>Yue</surname><given-names>HM</given-names></name><name><surname>Chen</surname><given-names>ZH</given-names></name><etal/></person-group><article-title>[Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study]</article-title><source>Zhonghua Gan Zang Bing Za Zhi</source><year>2020</year><volume>28</volume><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1007-3418.2020.02.003</pub-id><pub-id pub-id-type="pmid">32077660</pub-id></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>809</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30360-3</pub-id><pub-id pub-id-type="pmid">32151335</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Qiao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name></person-group><article-title>Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV</article-title><source>J Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jinf.2020.02.013</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><etal/></person-group><article-title>High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa</article-title><source>Int J Oral Sci</source><year>2020</year><volume>12</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1038/s41368-020-0074-x</pub-id><pub-id pub-id-type="pmid">32094336</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Ke</surname><given-names>A</given-names></name><etal/></person-group><article-title>Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection</article-title><source>bioRxiv</source><year>2020</year><volume>v1</volume><pub-id pub-id-type="doi">10.1101/2020.02.03.931766</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>GW</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>JW</given-names></name><name><surname>Wen</surname><given-names>XJ</given-names></name><name><surname>Mao</surname><given-names>TH</given-names></name><name><surname>Peng</surname><given-names>SW</given-names></name><etal/></person-group><article-title>[Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia]</article-title><source>Zhonghua Gan Zang Bing Za Zhi</source><year>2020</year><volume>28</volume><fpage>E002</fpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1007-3418.2020.02.002</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir Med</source><year>2020</year><pub-id pub-id-type="doi">10.1016/s2213-2600(20)30076-x</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgman</surname><given-names>MJ</given-names></name><name><surname>Garrard</surname><given-names>AR</given-names></name></person-group><article-title>A review of acetaminophen poisoning</article-title><source>Crit Care Clin</source><year>2012</year><volume>28</volume><fpage>499</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/j.ccc.2012.07.006</pub-id><pub-id pub-id-type="pmid">22998987</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krenzelok</surname><given-names>EP</given-names></name></person-group><article-title>The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member</article-title><source>Clin Toxicol (Phila)</source><year>2009</year><volume>47</volume><fpage>784</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1080/15563650903232345</pub-id><pub-id pub-id-type="pmid">19735211</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prompetchara</surname><given-names>E</given-names></name><name><surname>Ketloy</surname><given-names>C</given-names></name><name><surname>Palaga</surname><given-names>T</given-names></name></person-group><article-title>Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic</article-title><source>Asian Pac J Allergy Immunol</source><year>2020</year><volume>38</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.12932/ap-200220-0772</pub-id><pub-id pub-id-type="pmid">32105090</pub-id></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimstra</surname><given-names>WB</given-names></name><name><surname>Ryman</surname><given-names>KD</given-names></name><name><surname>Bernard</surname><given-names>KA</given-names></name><name><surname>Nguyen</surname><given-names>KB</given-names></name><name><surname>Biron</surname><given-names>CA</given-names></name><name><surname>Johnston</surname><given-names>RE</given-names></name></person-group><article-title>Infection of neonatal mice with sindbis virus results in a systemic inflammatory response syndrome</article-title><source>J Virol</source><year>1999</year><volume>73</volume><fpage>10387</fpage><lpage>10398</lpage><pub-id pub-id-type="pmid">10559357</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tartey</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name></person-group><article-title>Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells</article-title><source>Int Rev Immunol</source><year>2017</year><volume>36</volume><fpage>57</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1080/08830185.2016.1261318</pub-id><pub-id pub-id-type="pmid">28060562</pub-id></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Gui</surname><given-names>W</given-names></name><etal/></person-group><article-title>Creg in hepatocytes ameliorates liver ischemia/reperfusion injury in a TAK1-dependent manner in mice</article-title><source>Hepatology</source><year>2019</year><volume>69</volume><fpage>294</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1002/hep.30203</pub-id><pub-id pub-id-type="pmid">30076625</pub-id></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>ZZ</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/nm.4451</pub-id><pub-id pub-id-type="pmid">29227475</pub-id></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>ZL</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name></person-group><article-title>Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases</article-title><source>Virol Sin</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s12250-020-00203-8</pub-id></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Potential interventions for novel coronavirus in China: A systematic review</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><fpage>479</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1002/jmv.25707</pub-id><pub-id pub-id-type="pmid">32052466</pub-id></element-citation></ref><ref id="b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>RAS</given-names></name><name><surname>Sampaio</surname><given-names>WO</given-names></name><name><surname>Alzamora</surname><given-names>AC</given-names></name><name><surname>Motta-Santos</surname><given-names>D</given-names></name><name><surname>Alenina</surname><given-names>N</given-names></name><name><surname>Bader</surname><given-names>M</given-names></name><etal/></person-group><article-title>The ACE2/Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)</article-title><source>Physiol Rev</source><year>2018</year><volume>98</volume><fpage>505</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1152/physrev.00023.2016</pub-id><pub-id pub-id-type="pmid">29351514</pub-id></element-citation></ref><ref id="b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><etal/></person-group><article-title>The clinical pathology of severe acute respiratory syndrome (SARS): a report from China</article-title><source>J Pathol</source><year>2003</year><volume>200</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1002/path.1440</pub-id><pub-id pub-id-type="pmid">12845623</pub-id></element-citation></ref><ref id="b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>ML</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Sun</surname><given-names>YP</given-names></name><name><surname>Su</surname><given-names>GH</given-names></name></person-group><article-title>[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi</source><year>2020</year><volume>43</volume><fpage>E014</fpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1001-0939.2020.0014</pub-id><pub-id pub-id-type="pmid">32061198</pub-id></element-citation></ref><ref id="b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name></person-group><article-title>Potential natural compounds for preventing 2019-nCoV infection</article-title><source>Preprints</source><year>2020</year><fpage>2020010358(v3)</fpage><pub-id pub-id-type="doi">10.20944/preprints202001.0358.v3</pub-id></element-citation></ref><ref id="b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Cao</surname><given-names>HY</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>GH</given-names></name><name><surname>Sun</surname><given-names>MY</given-names></name></person-group><article-title>Glycyrrhizic acid in the treatment of liver diseases: literature review</article-title><source>Biomed Res Int</source><year>2014</year><volume>2014</volume><fpage>872139</fpage><pub-id pub-id-type="doi">10.1155/2014/872139</pub-id><pub-id pub-id-type="pmid">24963489</pub-id></element-citation></ref><ref id="b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>Structure of dimeric full-length human ACE2 in complex with B0ATI</article-title><source>bioRxiv</source><year>2020</year><volume>v1</volume><pub-id pub-id-type="doi">10.1101/2020.02.17.951848</pub-id></element-citation></ref><ref id="b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>ZJ</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name></person-group><article-title>2019 novel coronavirus: where we are and what we know</article-title><source>Infection</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s15010-020-01401-y</pub-id></element-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>ACE</term><def><p>angiotensin converting enzyme</p></def></def-item><def-item><term>ALT</term><def><p>alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p>aspartate aminotransferase</p></def></def-item><def-item><term>COVID-19</term><def><p>coronavirus disease 2019</p></def></def-item><def-item><term>SARS-CoV-2</term><def><p>severe acute respiratory syndrome coronavirus 2</p></def></def-item><def-item><term>TLR</term><def><p>toll-like receptor</p></def></def-item></def-list></glossary></back></article>